|
1.
|
Velez G, Weingarden AR, Lei H, Kazlauskas A, Gao G. SU9518 Inhibits Proliferative Vitreoretinopathy in Fibroblast and Genetically Modified Muller Cell-Induced Rabbit Models. Invest Ophthalmol Vis Sci. 2013; 54(2):1392-7.
|
|
|
|
|
2.
|
Velez G, Weingarden AR, Tucker BA, Lei H, Kazlauskas A, Young MJ. Retinal Pigment Epithelium and Müller Progenitor Cell Interaction Increase Müller Progenitor Cell Expression of PDGFRa and Ability to Induce Proliferative Vitreoretinopathy in a Rabbit Model. Stem Cells Int. 2012; 2012:106486.
|
|
|
|
|
3.
|
Lei H, Rhéaume MA, Velez G, Mukai S, Kazlauskas A. Expression of PDGFR{alpha} Is a Determinant of the PVR Potential of ARPE19 Cells. Invest Ophthalmol Vis Sci. 2011; 52(9):5016-21.
|
|
|
|
|
4.
|
Lei H, Velez G, Kazlauskas A. Pathological Signaling via Platelet-Derived Growth Factor Receptor {alpha} Involves Chronic Activation of Akt and Suppression of p53. Mol Cell Biol. 2011 May; 31(9):1788-99.
|
|
|
|
|
5.
|
Lei H, Velez G, Cui J, Samad A, Maberley D, Matsubara J, Kazlauskas A. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010 Jul; 177(1):132-40.
|
|
|
|
|
6.
|
Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci. 2009 Jul; 50(7):3394-403.
|
|
|
|
|
7.
|
Lei H, Velez G, Hovland P, Hirose T, Kazlauskas A. Plasmin is the major protease responsible for processing PDGF-C in the vitreous of patients with proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2008 Jan; 49(1):42-8.
|
|
|
|
|
8.
|
Lei H, Hovland P, Velez G, Haran A, Gilbertson D, Hirose T, Kazlauskas A. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007 May; 48(5):2335-42.
|
|
|
|
|
9.
|
Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ. A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease. Ocul Immunol Inflamm. 2007 Mar-Apr; 15(2):63-70.
|
|
|
|
|
10.
|
Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun. 2003 Nov; 21(3):283-93.
|
|
|
|
|
11.
|
Velez G, Weiter JJ. Cataract extraction and age-related macular degeneration: associations, diagnosis and management. Semin Ophthalmol. 2002 Sep-Dec; 17(3-4):187-95.
|
|
|
|
|
12.
|
Velez G, Boldt HC, Whitcup SM, Nussenblatt RB, Robinson MR. Local methotrexate and dexamethasone phosphate for the treatment of recurrent primary intraocular lymphoma. Ophthalmic Surg Lasers. 2002 Jul-Aug; 33(4):329-33.
|
|
|
|
|
13.
|
Velez G, Chan CC, Csaky KG. Fluorescein angiographic findings in primary intraocular lymphoma. Retina. 2002 Feb; 22(1):37-43.
|
|
|
|
